Zhao Ying, Wang Hai
Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing 100853.
Research Division of Pharmacology, the Fifth Medical Center of PLA General Hospital, Beijing 100853, China.
Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2022 Nov;38(6):604-610. doi: 10.12047/j.cjap.6356.2022.110.
To investigate the interventional effects of a new SUR2B/Kir6.1-type K Channel opener iptakalim on injury renal cells (the renal glomerular endothelial, mesangial and tubular epithelial cells) and its mechanisms. ①Experimental protocol: control: the cells were treated with with 0 mg/L uric acid for 24 h; model: the cells were treated with with 1 200 mg/L uric acid for 24 h; pretreatment with iptakalim: the cells were pretreated with 0.01,0.1,1,10,100 μmol/L iptakalim for 24 h prior to treatment with 1 200 mg/L uric acid for 24 h; pretreatment with glibenclamide: the cells were preincubated with/without 10 μmol/L glibenclamide for 1 h and then treated with 10 μmol/L iptakalim for 24 h followed by incubation with 1 200 mg/L uric acid for another 24 h. ②The cell viability was measured by MTT assay and flow cytometry; the protein expressions of Kir6.1 and SUR2B and nuclear translocation were detected by immunostaining; the protein expressions of Kir6.1 and SUR2B were determined by Western blot analysis; adhesion of mononuclear cells to endothelial cells were tested by fluorimetric assay; the content of MCP-1 was measured by enzyme linked-immunosorbent assay (ELISA). The renal glomerular endothelial, mesangial and tubular epithelial cells were exposed to 1 200 mg/L uric acid for 24 h. Compared with the control group, 1 200 mg/L uric acid decreased the cell survival rates significantly (<0.01, <0.01, <0.01). Compared with the model group, pretreatment with 0.1, 1, 10, 100 μmol/L iptakalim could remarkably alleviate cellular damages of glomerular endothelium, mesangium cells induced by uric acid (<0.05, <0.01, <0.01, <0.01). The K channel blocker could clearly reduce survival rates of the renal glomerular endothelial, mesangial cells(<0.01) and markedly reverse the inhibitory effects of iptakalim on cell death (<0.05, <0.01), no obvious difference in comparison with the model group (>0.05). Compared with the model group, pretreatment with 10, 100 μmol/L iptakalim could notably attenuate cellular damages of tubular epithelial cells induced by uric acid (<0.05, <0.05). The K channel blocker could obviously damage the tubular epithelial cells (<0.01), no obvious difference in comparison with the model group (>0.05). Compared with control group, exposure of renal tubular epithelial, mesangial and glomerular endothelial cells to 1 200 mg/L uric acid for 24 h caused a significant increase in the protein expressions of Kir6.1 and SUR2B(<0.05). Compared with the model group, the overexpressions of Kir6.1 and SUR2B were suppressed in presence of iptakalim at a concentration of 10 μmol/L (<0.05). These decreases in the expressions of Kir6.1 and SUR2B were prevented by the K channel blocker, no obvious difference in comparison with the model group (>0.05). Compare with the control group, monocytic adhesion to renal glomerular endothelial cells was notably promoted by 1 200 mg/L uric acid for 24 h (<0.01). Pretreatment with 10 μmol/L iptakalim for 24 h significantly reduced the monocytic adhesion in comparison with the model group (<0.05). It was showed that the inhibitory effects of iptakalim were antagonized by the K channel blocker, no obvious difference in comparison with the model group (>0.05). After stimulating glomerular endothelial cells with 1 200 mg/L uric acid for 24 hours, the secretion of MCP-1 was significantly increased compared to the control group (<0.05). Compare with the model group, preincubation with 10 μmol/L iptakalim significantly decreased MCP-1 production (<0.05). K channel blocker suppressed the downregulation of MCP-1 protein synthesis induced by iptakalim. After stimulation with uric acid, translocation of NF-κB from cytoplasms to nuclei of renal glomerular endothelial cells were observed, while that of NF-κB was suppressed in presence of iptakalim at the concentration of 10 μmol/L. This inhibition of NF-κB translocation was clearly prevented by K channel blocker. These results suggests that a new SUR2B/Kir6.1-type K channel opener iptakalim plays interventional roles in renal cells damages caused by uirc acid and its mechanism is involved in activating Kchannels .
探讨新型SUR2B/Kir6.1型钾通道开放剂伊伐卡林对损伤肾细胞(肾小球内皮细胞、系膜细胞和肾小管上皮细胞)的干预作用及其机制。①实验方案:对照组:细胞用0mg/L尿酸处理24小时;模型组:细胞用1200mg/L尿酸处理24小时;伊伐卡林预处理组:细胞在用1200mg/L尿酸处理24小时前,先用0.01、0.1、1、10、100μmol/L伊伐卡林预处理24小时;格列本脲预处理组:细胞先在有无10μmol/L格列本脲的条件下预孵育1小时,然后用10μmol/L伊伐卡林处理24小时,接着再用1200mg/L尿酸孵育24小时。②采用MTT法和流式细胞术检测细胞活力;通过免疫染色检测Kir6.1和SUR2B的蛋白表达及核转位;用蛋白质印迹分析测定Kir6.1和SUR2B的蛋白表达;通过荧光测定法检测单核细胞与内皮细胞的黏附;用酶联免疫吸附测定法(ELISA)检测MCP-1的含量。将肾小球内皮细胞、系膜细胞和肾小管上皮细胞暴露于1200mg/L尿酸中24小时。与对照组相比,1200mg/L尿酸显著降低细胞存活率(<0.01,<0.01,<0.01)。与模型组相比,用0.1、1、10、100μmol/L伊伐卡林预处理可显著减轻尿酸诱导的肾小球内皮、系膜细胞的细胞损伤(<0.05,<0.01,<0.01,<0.01)。钾通道阻滞剂可明显降低肾小球内皮、系膜细胞的存活率(<0.01),并显著逆转伊伐卡林对细胞死亡的抑制作用(<0.05,<0.01),与模型组相比无明显差异(>0.05)。与模型组相比,用10、100μmol/L伊伐卡林预处理可显著减轻尿酸诱导的肾小管上皮细胞的细胞损伤(<0.05,<0.05)。钾通道阻滞剂可明显损伤肾小管上皮细胞(<0.01),与模型组相比无明显差异(>0.05)。与对照组相比,将肾小管上皮细胞、系膜细胞和肾小球内皮细胞暴露于1200mg/L尿酸中24小时可导致Kir6.1和SUR2B的蛋白表达显著增加(<0.05)。与模型组相比,在10μmol/L伊伐卡林存在的情况下,Kir6.1和SUR2B的过表达受到抑制(<0.05)。钾通道阻滞剂可阻止Kir6.1和SUR2B表达的这些降低,与模型组相比无明显差异(>0.05)。与对照组相比,1200mg/L尿酸处理24小时可显著促进单核细胞对肾小球内皮细胞的黏附(<0.01)。用10μmol/L伊伐卡林预处理24小时与模型组相比可显著降低单核细胞黏附(<0.05)。结果表明,钾通道阻滞剂可拮抗伊伐卡林的抑制作用,与模型组相比无明显差异(>0.05)。用1200mg/L尿酸刺激肾小球内皮细胞24小时后,与对照组相比,MCP-1的分泌显著增加(<0.05)。与模型组相比,用10μmol/L伊伐卡林预孵育可显著降低MCP-1的产生(<0.05)。钾通道阻滞剂抑制了伊伐卡林诱导的MCP-1蛋白合成的下调。尿酸刺激后,观察到肾小球内皮细胞核因子κB从细胞质向细胞核的转位,而在10μmol/L伊伐卡林存在的情况下,核因子κB的转位受到抑制。钾通道阻滞剂可明显阻止这种核因子κB转位的抑制作用。这些结果表明,新型SUR2B/Kir6.1型钾通道开放剂伊伐卡林对尿酸引起的肾细胞损伤具有干预作用,其机制与激活钾通道有关。